Loeillot Olivier
Known title: President and CCOCIK: 0001995525
Associated companies
Transaction History
| RGEN | ▲ Buy | Option Exercise | 8,404 | $1.3M | 9/24/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 8,404 | $1.6M | 9/24/2026 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 4,542 | $706K | 9/24/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 4,542 | $863K | 9/24/2026 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 5,426 | $769K | 9/21/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 5,426 | $977K | 9/21/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 3,035 | $504K | 9/4/2026 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 2,842 | $482K | 9/3/2026 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 5,426 | $769K | 8/20/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 5,426 | $977K | 8/20/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 3,832 | $536K | 4/21/2026 | View on chart |
| RGEN | ▲ Buy | Grant | 24,134 | $0 | 3/5/2026 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 1,610 | $201K | 3/2/2026 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 344 | $44K | 2/27/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 7,041 | $1.2M | 11/25/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 1,248 | $181K | 10/2/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 2,506 | $291K | 9/3/2025 | View on chart |
| RGEN | ▲ Buy | Grant | 14,480 | $0 | 3/3/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 343 | $54K | 2/27/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 861 | $106K | 11/20/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 17,631 | $0 | 9/3/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 2,880 | $0 | 2/27/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 12,906 | $0 | 10/2/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.